NCT00112372View on ClinicalTrials.gov

Study of Oral Ridaforolimus (AP23573, MK-8669) to Treat Patients With Refractory or Advanced Malignancies (MK-8669-016 AM4)(COMPLETED)

PHASE1CompletedINTERVENTIONAL

Enrollment

147

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

December 31, 2008

Study Completion Date

March 31, 2009

Conditions

Cancer

Interventions

DRUG

Ridaforolimus

10 mg tablet of ridaforolimus administered orally according to one of several different dosing regimens for a four-week treatment cycle.

Sponsors

Collaborators (1)

Ariad Pharmaceuticals

All Listed Sponsors

collaborator

Ariad Pharmaceuticals

INDUSTRY

lead

Merck Sharp & Dohme LLC

INDUSTRY